Disposition of 5000 shares by Robert Blum of Cytokinetics at 6.67 subject to Rule 16b-3

FBTTX Fund  USD 28.60  0.20  0.69%   
Slightly above 62% of Fidelity Advisor's investor base is looking to short. The analysis of overall sentiment of trading Fidelity Advisor Biotechnology mutual fund suggests that many investors are alarmed at this time. Fidelity Advisor's investing sentiment can be driven by a variety of factors including economic data, Fidelity Advisor's earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Cytokinetics Director, Officer: President & Ceo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at investing.com
Investing News at Macroaxis
  
Disposition of 5000 non-qualified stock option (right to buy) at 6.67 of Cytokinetics by Robert Blum on 18th of November 2024. This event was filed by Cytokinetics with SEC on 2024-11-18. Statement of changes in beneficial ownership - SEC Form 4. Robert Blum currently serves as ceo and president director and chief executive of the biopharmaceutical concern of Cytokinetics

Fidelity Advisor Fundamental Analysis

We analyze Fidelity Advisor's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fidelity Advisor using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fidelity Advisor based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

One Year Return

One Year Return Comparative Analysis

Fidelity Advisor is currently under evaluation in one year return among similar funds. One Year Return is the annualized return generated from holding a security for exactly 12 months. The measure is considered to be good short-term measures of fund performance. In other words, it represents the capital appreciation of fund investments over the last year. However when the market is volatile such as in recent years, One Year Return measure can be misleading.

Fidelity Advisor Bio Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Fidelity Advisor mutual fund to make a market-neutral strategy. Peer analysis of Fidelity Advisor could also be used in its relative valuation, which is a method of valuing Fidelity Advisor by comparing valuation metrics with similar companies.

Other Information on Investing in Fidelity Mutual Fund

Fidelity Advisor financial ratios help investors to determine whether Fidelity Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Fidelity with respect to the benefits of owning Fidelity Advisor security.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Equity Valuation
Check real value of public entities based on technical and fundamental data